Multicentric Cardiac Myxoma Treated with Extended Surgery

We present the case of a 37-year-old male patient with a multicentric myxoma admitted to hospital with dyspnoea, syncope and chest pain. Physical examination revealed a grade 3/6 systolic murmur at the left lower sternal border and diffuse bilateral lung rales. Transthoracic echocardiography and thoraco-abdominal computed tomography revealed a right atrial mass and a right ventricular mass obstructing the outflow tract. The patient underwent urgent surgical treatment. At operation, a solitary right atrial myxoma and a right ventricular myxoma originating from the tricuspid valve and attached to the free wall of the right ventricle were seen. The tumours were successfully excised and the tricuspid valve was replaced with a No. 33 Omnicarbon® metallic valve. The right ventricular free wall was repaired with a glutaraldehyde-treated pericardial patch. Histopathological examination of the tumours confirmed the diagnosis of myxoma. Post-operative recovery was uneventful and there was no recurrence after 1 year's follow-up.

Measurement of the centrality dependence of the charged-particle pseudorapidity distribution in proton-lead collisions at [Formula: see text] TeV with the ATLAS detector

The centrality dependence of the mean charged-particle multiplicity as a function of pseudorapidity is measured in approximately 1 [Formula: see text]b[Formula: see text] of proton-lead collisions at a nucleon-nucleon centre-of-mass energy of [Formula: see text] [Formula: see text] using the ATLAS detector at the Large Hadron Collider. Charged particles with absolute pseudorapidity less than 2.7 are reconstructed using the ATLAS pixel detector. The [Formula: see text] collision centrality is characterised by the total transverse energy measured in the Pb-going direction of the forward calorimeter. The charged-particle pseudorapidity distributions are found to vary strongly with centrality, with an increasing asymmetry between the proton-going and Pb-going directions as the collisions become more central. Three different estimations of the number of nucleons participating in the [Formula: see text] collision have been carried out using the Glauber model as well as two Glauber-Gribov inspired extensions to the Glauber model. Charged-particle multiplicities per participant pair are found to vary differently for these three models, highlighting the importance of including colour fluctuations in nucleon-nucleon collisions in the modelling of the initial state of [Formula: see text] collisions.

Differential expression of LOXL4 in normal and tumour tissue samples of laryngeal squamous cell carcinoma

OBJECTIVE

Head and neck cancer is the sixth most common cancer in worldwide with an increasing incidence rate in recent years. LOXL4 is expressed in several tissues, and its expression has been shown to display a significant correlation with local lymph node metastasis. In this study, we aimed to explore the LOXL4 expression level in metastatic and non-metastatic LSCC tissues and to determine its prognostic significance.

STUDY DESIGN

Basic science research study.

SETTING

University hospital.

PARTICIPANTS

A total of 40 patients were included in the study.

MAIN OUTCOME MEASURE

LOXL4 expression status in metastatic, non-metastatic LSCC and normal tissue samples was investigated by quantitative reverse-transcription PCR.

RESULTS

We demonstrated that LOXL4 was significantly overexpressed in LSCC tumour tissue samples in comparison with the corresponding normal tissues (P < 0.001); however, no significant relationship has been found between LOXL4 expression and either the metastatic potential or the T classification of the specimens.

CONCLUSIONS

Although expression of LOXL4 is not statistically associated with neck metastases, we showed that LOXL4 expression significantly increased in laryngeal cancer.

Antenna-type radiofrequency generator in nanoparticle-mediated hyperthermia

This study covers the employment an antenna-type RF generator modulus at varying powers for different nanoparticle types to evaluate viability, apoptosis and necrosis of L-929 fibroblast and MCF-7 breast cancer cell lines.

A case of Cantrell syndrome diagnosed in the first trimester

Here, the authors report a case of Cantrell's syndrome which was diagnosed by ultrasound at 12th week of pregnancy and confirmed by autopsy. Cantrell syndrome/pentalogy is defined as congenital combination of five main distinctive components: defects at the lower part of the sternum, anterior diaphragm, midline supraumbilical abdominal wall, diaphragmatic pericardium, and ectopia cordis. In the present case, in addition to these anomalies, there was cleft palate and cleft lip at the midline. Association of cleft lip and palate with Cantrell's syndrome may be due to the extension of defective migration of mesodennal primordial structures, which is mainly in abdomen and thorax, towards facial structures. Therefore, in prenatal diagnosis facial anomalies should be examined carefully in all cases with Cantrell syndrome.

The fabrication of plasmonic nanoparticle-containing multilayer films via a bio-inspired polydopamine coating

A simple approach for the fabrication of plasmonic nanoparticle-containing multilayer films using a bio-inspired polydopamine coating was demonstrated.

Denis RD, Staerz S, Stahlman J, Stamen R, Stamm S, Stanecka E, Stanek RW, Stanescu C, Stanescu-Bellu M, Stanitzki MM, Stapnes S, Starchenko EA, Stark J, Staroba P, Starovoitov P, Staszewski R, Stavina P, Steinberg P, Stelzer B, Stelzer HJ, Stelzer-Chilton O, Stenzel H, Stern S, Stewart GA, Stillings JA, Stockton MC, Stoebe M, Stoicea G, Stolte P, Stonjek S, Stradling AR, Straessner A, Stramaglia ME, Strandberg J, Strandberg S, Strandlie A, Strauss E, Strauss M, Strizenec P, Ströhmer R, Strom DM, Stroynowski R, Strubig A, Stucci SA, Stugu B, Styles NA, Su D, Su J, Subramaniam R, Succurro A, Sugaya Y, Suhr C, Suk M, Sulin VV, Sultansoy S, Sumida T, Sun S, Sun X, Sundermann JE, Suruliz K, Susinno G, Sutton MR, Suzuki Y, Svatos M, Swedish S, Swiatlowski M, Sykora I, Sykora T, Ta D, Taccini C, Tackmann K, Taenzer J, Taffard A, Tafirout R, Taiblum N, Takai H, Takashima R, Takeda H, Takeshita T, Takubo Y, Talby M, Talyshev AA, Tam JYC, Tan KG, Tanaka J, Tanaka R, Tanaka S, Tanaka S, Tanasijczuk AJ, Tannenwald BB, Tannoury N, Tapprogge S, Tarem S, Tarrade F, Tartarelli GF, Tas P, Tasevsky M, Tashiro T, Tassi E, Tavares Delgado A, Tayalati Y, Taylor FE, Taylor GN, Taylor W, Teischinger FA, Teixeira Dias Castanheira M, Teixeira-Dias P, Temming KK, Ten Kate H, Teng PK, Teoh JJ, Terada S, Terashi K, Terron J, Terzo S, Testa M, Teuscher RJ, Therhaag J, Theveneaux-Pelzer T, Thomas JP, Thomas-Wilsker J, Thompson EN, Thompson PD, Thompson PD, Thompson RJ, Thompson AS, Thomsen LA, Thomson E, Thomson M, Thong WM, Thun RP, Tian F, Tibbetts MJ, Tikhomirov VO, Tikhonov YA, Timoshenko S, Tiouchichine E, Tipton P, Tisserant S, Todorov T, Todorova-Nova S, Toggerson B, Tojo J, Tokár S, Tokushuku K, Tollefson K, Tolley E, Tomlinson L, Tomoto M, Tompkins L, Toms K, Topilin ND, Torrence E, Torres H, Torró Pastor E, Toth J, Touchard F, Tovey DR, Tran HL, Trefzger T, Tremblet L, Tricoli A, Trigger IM, Trincaz-Duvoid S, Tripiana MF, Trischuk W, Trocmé B, Troncon C, Trottier-McDonald M, Trovatelli M, True P, Trzebinski M, Trzupek A, Tsarouchas C, Tseng JCL, Tsiareshka PV, Tsionou D, Tsipolitis G, Tsirintanis N, Tsiskaridze S, Tsiskaridze V, Tskhadadze EG, Tsukerman II, Tsulaia V, Tsuno S, Tsybychev D, Tudorache A, Tudorache V, Tuna AN, Tupputi SA, Turchikhin S, Turecek D, Turra R, Tuts PM, Tykhonov A, Tylmad M, Tyndel M, Uchida K, Ueda I, Ueno R, Ughetto M, Ugland M, Uhlenbrock M, Ukegawa F, Unal G, Undrus A, Unel G, Ungaro FC, Unno Y, Unverdorben C, Urbaniec D, Urquijo P, Usai G, Usanova A, Vacavant L, Vacek V, Vachon B, Valencic N, Valentinetti S, Valero A, Valery L, Valkar S, Valladolid Gallego E, Vallecorsa S, Valls Ferrer JA, Van Den Wollenberg W, Van Der Deijl PC, van der Geer R, van der Graaf H, Van Der Leeuw R, van der Ster D, van Eldik N, van Gemmeren P, Van Nieuwkoop J, van Vulpen I, van Woerden MC, Vanadia M, Vandelli W, Vanguri R, Vaniachine A, Vannucci F, Vardanyan G, Vari R, Varnes EW, Varol T, Varouchas D, Vartapetian A, Varvell KE, Vazeille F, Vazquez Schroeder T, Veatch J, Veloso F, Velz T, Veneziano S, Ventura A, Ventura D, Venturi M, Venturi N, Venturini A, Vercesi V, Verducci M, Verkerke W, Vermeulen JC, Vest A, Vetterli MC, Viazlo O, Vichou I, Vickey T, Vickey Boeriu OE, Viehhauser GHA, Viel S, Vigne R, Villa M, Villaplana Perez M, Vilucchi E, Vincter MG, Vinogradov VB, Virzi J, Vivarelli I, Vives Vaque F, Vlachos S, Vladoiu D, Vlasak M, Vogel A, Vogel M, Vokac P, Volpi G, Volpi M, von der Schmitt H, von Radziewski H, von Toerne E, Vorobel V, Vorobev K, Vos M, Voss R, Vossebeld JH, Vranjes N, Vranjes Milosavljevic M, Vrba V, Vreeswijk M, Vu Anh T, Vuillermet R, Vukotic I, Vykydal Z, Wagner P, Wagner W, Wahlberg H, Wahrmund S, Wakabayashi J, Walder J, Walker R, Walkowiak W, Wall R, Waller P, Walsh B, Wang C, Wang C, Wang F, Wang H, Wang H, Wang J, Wang J, Wang K, Wang R, Wang SM, Wang T, Wang X, Wanotayaroj C, Warburton A, Ward CP, Wardrope DR, Warsinsky M, Washbrook A, Wasicki C, Watkins PM, Watson AT, Watson IJ, Watson MF, Watts G, Watts S, Waugh BM, Webb S, Weber MS, Weber SW, Webster JS, Weidberg AR, Weigell P, Weinert B, Weingarten J, Weiser C, Weits H, Wells PS, Wenaus T, Wendland D, Weng Z, Wengler T, Wenig S, Wermes N, Werner M, Werner P, Wessels M, Wetter J, Whalen K, White A, White MJ, White R, White S, Whiteson D, Wicke D, Wickens FJ, Wiedenmann W, Wielers M, Wienemann P, Wiglesworth C, Wiik-Fuchs LAM, Wijeratne PA, Wildauer A, Wildt MA, Wilkens HG, Will JZ, Williams HH, Williams S, Willis C, Willocq S, Wilson A, Wilson JA, Wingerter-Seez I, Winklmeier F, Winter BT, Wittgen M, Wittig T, Wittkowski J, Wollstadt SJ, Wolter MW, Wolters H, Wosiek BK, Wotschack J, Woudstra MJ, Wozniak KW, Wright M, Wu M, Wu SL, Wu X, Wu Y, Wulf E, Wyatt TR, Wynne BM, Xella S, Xiao M, Xu D, Xu L, Yabsley B, Yacoob S, Yakabe R, Yamada M, Yamaguchi H, Yamaguchi Y, Yamamoto A, Yamamoto K, Yamamoto S, Yamamura T, Yamanaka T, Yamauchi K, Yamazaki Y, Yan Z, Yang H, Yang H, Yang UK, Yang Y, Yanush S, Yao L, Yao WM, Yasu Y, Yatsenko E, Yau Wong KH, Ye J, Ye S, Yeletskikh I, Yen AL, Yildirim E, Yilmaz M, Yoosoofmiya R, Yorita K, Yoshida R, Yoshihara K, Young C, Young CJS, Youssef S, Yu DR, Yu J, Yu JM, Yu J, Yuan L, Yurkewicz A, Yusuff I, Zabinski B, Zaidan R, Zaitsev AM, Zaman A, Zambito S, Zanello L, Zanzi D, Zeitnitz C, Zeman M, Zemla A, Zengel K, Zenin O, Ženiš T, Zerwas D, Zevi della Porta G, Zhang D, Zhang F, Zhang H, Zhang J, Zhang L, Zhang X, Zhang Z, Zhao Z, Zhemchugov A, Zhong J, Zhou B, Zhou L, Zhou N, Zhu CG, Zhu H, Zhu J, Zhu Y, Zhuang X, Zhukov K, Zibell A, Zieminska D, Zimine NI, Zimmermann C, Zimmermann R, Zimmermann S, Zimmermann S, Zinonos Z, Ziolkowski M, Zobernig G, Zoccoli A, zur Nedden M, Zurzolo G, Zutshi V, Zwalinski L. Two-particle Bose-Einstein correlations in pp collisions at [Formula: see text] 0.9 and 7 TeV measured with the ATLAS detector

The paper presents studies of Bose-Einstein Correlations (BEC) for pairs of like-sign charged particles measured in the kinematic range [Formula: see text] 100 MeV and [Formula: see text] 2.5 in proton collisions at centre-of-mass energies of 0.9 and 7 TeV with the ATLAS detector at the CERN Large Hadron Collider. The integrated luminosities are approximately 7 [Formula: see text]b[Formula: see text], 190 [Formula: see text]b[Formula: see text] and 12.4 nb[Formula: see text] for 0.9 TeV, 7 TeV minimum-bias and 7 TeV high-multiplicity data samples, respectively. The multiplicity dependence of the BEC parameters characterizing the correlation strength and the correlation source size are investigated for charged-particle multiplicities of up to 240. A saturation effect in the multiplicity dependence of the correlation source size parameter is observed using the high-multiplicity 7 TeV data sample. The dependence of the BEC parameters on the average transverse momentum of the particle pair is also investigated.

Assessment of left atrial functions in cardiac syndrome X

OBJECTIVE

Cardiac syndrome X (CSX) affects left ventricular functions due to myocardial ischaemia. In this study our aim was to determine the changes in left atrial functions in patients with CSX.

PATIENTS AND METHODS

One-hundred patients (M/F; 57/43) diagnosed with CSX in whom ischaemia was detected at exercise test and myocardial perfusion scintigrapghy with normal coronary angiogram and control group of 80 subjects (M/F; 40/40) were recruited into the study. In transthoracic echocardiography and tissue doppler echocardiography, left ventricular and atrial functions were recorded.

RESULTS

As compared to control group,left ventricular diastolic functions were impaired (E/A; 0.95 ± 0.18 vs 1.11 ± 0.29 p < 0.001), left ventricular end-diastolic pressures were increased (E/Em; 8.1 ± 1.85 vs 6.9 ± 1.74 p < 0.05), and left atrial maximum volume, left atrial pre-A volume,left atrial minimum volume were increased in patients with CSX. Left atrial conduit volume was significantly decreased in patients with cardiac syndrome. Left atrial passive emptying volume (LAPEV), left atrial active emptying volume (LAAEV) and left atrial total emptying volume (LATEV) were significantly increased in patients with cardiac syndrome X. Left atrial passive ejection fration (LAPEF) was found similar between the study groups.Left atrial active ejection fraction (LAAEF) was found significantly increased (37.85 ± 11.89 vs 33.60 ± 9.21; p = 0.009) in patients with CSX. Left atrial total ejection fraction (LATEF) was increased in the group with cardiac syndrome X but it didn't reach statistical significance (60.85 ± 8.73 vs 58.36 ± 8.29; p = 0.054).

CONCLUSIONS

Left atrial active contractile pump function increase in response to impaired left ventricular diastolic functions in CSX. Increased left atrial pump function represents a compensatory mechanism in patients with CSX. These results point out the importance of maintaining sinus rythm in patients with CSX.

Identification and energy calibration of hadronically decaying tau leptons with the ATLAS experiment in pp collisions at [Formula: see text][Formula: see text]

This paper describes the trigger and offline reconstruction, identification and energy calibration algorithms for hadronic decays of tau leptons employed for the data collected from pp collisions in 2012 with the ATLAS detector at the LHC center-of-mass energy [Formula: see text] [Formula: see text]. The performance of these algorithms is measured in most cases with [Formula: see text] decays to tau leptons using the full 2012 dataset, corresponding to an integrated luminosity of 20.3 fb[Formula: see text]. An uncertainty on the offline reconstructed tau energy scale of 2-4 %, depending on transverse energy and pseudorapidity, is achieved using two independent methods. The offline tau identification efficiency is measured with a precision of 2.5 % for hadronically decaying tau leptons with one associated track, and of 4 % for the case of three associated tracks, inclusive in pseudorapidity and for a visible transverse energy greater than 20 [Formula: see text]. For hadronic tau lepton decays selected by offline algorithms, the tau trigger identification efficiency is measured with a precision of 2-8 %, depending on the transverse energy. The performance of the tau algorithms, both offline and at the trigger level, is found to be stable with respect to the number of concurrent proton-proton interactions and has supported a variety of physics results using hadronically decaying tau leptons at ATLAS.

HDL-cholesterol is associated with systemic inflammation in cardiac syndrome X

AIM

Microvascular inflammation is associated with cardiac syndrome X (CSX). High-density lipoprotein cholesterol (HDL-C) reveals antiatherogenic features with stimulating endothelial NO production, inhibiting oxidative stress and vascular inflammation. We investigated relationship between HDL-C and inflammatory markers in CSX.

METHODS

Hundred patients with CSX and control group of 80 subjects were evaluated. Hematologic indices, lipid levels and C-reactive protein (CRP) levels were studied in patients underwent coronary angiography.

RESULTS

CRP levels were higher in CSX group than control group (4.59 ± 3.82 mg/dL vs. 2.48 ± 1.32 mg/dL, P<0.001). HDL-C was significantly lower in CSX group compared to control group (36.5 ± 4.0 mg/dL vs. 47.5 ± 12.7 mg/dL, P=0.008). White blood cell (WBC) count was higher in CSX group than in control group. Neutrophil-lymphocyte ratio (NLR) was found significantly increased in CSX group as compared to control group. On multivariate linear regression, lower HDL-C was found to be a significant predictor of higher NLR in patients with CSX independent from other clinical and biochemical variables.

CONCLUSION

Lower HDL-C is associated with systemic inflammation in CSX. In patients with typical angina and normal epicardial coronaries,HDL-C and inflammatory markers should be investigated; one of the goals of treatment should be raising HDL-C.